Skip to main content
. 2015 May 20;2015(5):CD007929. doi: 10.1002/14651858.CD007929.pub3

Comparison 1.

PARP inhibitors versus other treatments or placebo

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Overall survival 3 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 PARP inhibitor versus other monotherapy 1 97 Hazard Ratio (Random, 95% CI) 0.82 [0.00, 211083.92]
1.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) 1 162 Hazard Ratio (Random, 95% CI) 1.17 [0.79, 1.74]
1.3 PARP inhibitor versus placebo (as maintenance) 1 264 Hazard Ratio (Random, 95% CI) 0.94 [0.63, 1.40]
2 Overall survival (platinum‐sensitive only) 2 426 Hazard Ratio (Random, 95% CI) 1.05 [0.79, 1.39]
2.1 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) 1 162 Hazard Ratio (Random, 95% CI) 1.17 [0.79, 1.74]
2.2 PARP inhibitor versus placebo (as maintenance) 1 264 Hazard Ratio (Random, 95% CI) 0.94 [0.63, 1.40]
3 Progression‐free survival 4 Hazard Ratio (Random, 95% CI) Subtotals only
3.1 PARP inhibitor versus other monotherapy 1 97 Hazard Ratio (Random, 95% CI) 0.88 [0.51, 1.52]
3.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) 2 237 Hazard Ratio (Random, 95% CI) 0.72 [0.37, 1.43]
3.3 PARP inhibitor versus placebo (as maintenance) 1 264 Hazard Ratio (Random, 95% CI) 0.35 [0.25, 0.49]
4 Progression‐free survival (platinum‐sensitive only) 2 426 Hazard Ratio (Random, 95% CI) 0.42 [0.29, 0.60]
4.1 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) 1 162 Hazard Ratio (Random, 95% CI) 0.51 [0.34, 0.77]
4.2 PARP inhibitor versus placebo (as maintenance) 1 264 Hazard Ratio (Random, 95% CI) 0.35 [0.25, 0.49]
5 Objective response rate (RECIST) (no response) 4 434 Risk Ratio (IV, Random, 95% CI) 0.90 [0.82, 0.99]
5.1 PARP inhibitor versus other monotherapy 1 97 Risk Ratio (IV, Random, 95% CI) 0.88 [0.70, 1.10]
5.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) 2 232 Risk Ratio (IV, Random, 95% CI) 0.82 [0.57, 1.19]
5.3 PARP inhibitor versus placebo (as maintenance) 1 105 Risk Ratio (IV, Random, 95% CI) 0.92 [0.82, 1.03]
6 Severe adverse events 4 Risk Ratio (IV, Random, 95% CI) Subtotals only
6.1 Nausea (G3‐4) 4 592 Risk Ratio (IV, Random, 95% CI) 1.23 [0.33, 4.60]
6.2 Diarrhoea (G3‐4) 4 592 Risk Ratio (IV, Random, 95% CI) 0.53 [0.15, 1.90]
6.3 Vomiting (G3‐4) 4 592 Risk Ratio (IV, Random, 95% CI) 1.42 [0.25, 8.10]
6.4 Stomatitis (any grade) 3 503 Risk Ratio (IV, Random, 95% CI) 0.44 [0.02, 10.15]
6.5 Anaemia (G3‐4) 4 592 Risk Ratio (IV, Random, 95% CI) 2.15 [0.89, 5.21]
6.6 Neutropenia (G3‐4) 2 220 Risk Ratio (IV, Random, 95% CI) 0.59 [0.09, 3.98]
6.7 Other (G3‐4) 3 483 Risk Ratio (IV, Random, 95% CI) 1.06 [0.16, 6.98]
6.8 Any SAE 1 156 Risk Ratio (IV, Random, 95% CI) 1.14 [0.89, 1.47]
7 Adverse event during maintenance (any grade) 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
7.1 Nausea 2 385 Risk Ratio (IV, Random, 95% CI) 3.82 [0.85, 17.22]
7.2 Anaemia 2 385 Risk Ratio (IV, Random, 95% CI) 2.30 [0.87, 6.08]
7.3 Fatigue 2 385 Risk Ratio (IV, Random, 95% CI) 1.35 [1.02, 1.78]
8 Adverse event during maintenance (grade 3/4) 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
8.1 Nausea 2 385 Risk Ratio (IV, Random, 95% CI) 4.21 [0.48, 36.69]
8.2 Anaemia 2 385 Risk Ratio (IV, Random, 95% CI) 5.26 [1.19, 23.20]
8.3 Fatigue 2 385 Risk Ratio (IV, Random, 95% CI) 2.12 [0.67, 6.71]
9 Any adverse event during maintenance (any grade) 2 385 Risk Ratio (IV, Random, 95% CI) 1.16 [0.94, 1.42]
10 Any adverse event during maintenance (grade 3/4) 2 385 Risk Ratio (IV, Random, 95% CI) 1.74 [1.22, 2.49]